ArticleMedical oncology (Northwood, London, England)2012
Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma.
Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Low NDRG2 expression predicts poor prognosis in solid tumors: A meta-analysis of cohort study.Medicine · 2020Pooled it
- The Function of N-Myc Downstream-Regulated Gene 2 (NDRG2) as a Negative Regulator in Tumor Cell Metastasis.International journal of molecular sciences · 2022Review
- Radiation-induced gastrointestinal syndrome is alleviated in NDRG2-deficient mice.Journal of gastrointestinal oncology · 2021Article
- NDRG2 gene expression pattern in ovarian cancer and its specific roles in inhibiting cancer cell proliferation and suppressing cancer cell apoptosis.Journal of ovarian research · 2020Article
- Review
- Downregulation of CD99 and upregulation of human leukocyte antigen class II promote tumor aggravation and poor survival in patients with osteosarcomas.OncoTargets and therapy · 2014Article
- CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2.Oncology letters · 2013Article
- Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Article
- Targeted Overexpression of NDRG2 using Survivin Promoter Reduces Viability and Invasiveness of A549 Cell Line.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-Myc downstream-regulated gene 2 (NDRG2) has been demonstrated to influence the metastatic potential of hepatocellular carcinoma and breast cancer cells by regulating CD24 expression. The aim of this study was to investigate the roles of NDRG2 and CD24 in the clinical pathology of lung adenocarcinoma and to explore whether the expression of these two markers can be used as independent factors for the prediction of prognosis in patients with this tumor. NDRG2 and CD24 expression in paraffin-embedded specimens gathered from 166 patients with lung adenocarcinoma was detected by immunohistochemical method. The correlation of these two proteins expression with clinicopathological parameters and prognosis was statistically analyzed. NDRG2 and CD24 proteins were highly expressed in 59/166 (35.5 %) and 110/166 (66.3 %) of lung adenocarcinoma patients, respectively. High expression of NDRG2 was frequently found in lung adenocarcinoma tissues in early pTNM stage (p = 0.01) and without pathological metastasis (p = 0.02), whereas the high expression of CD24 was significantly associated with the advanced pTNM stage (p = 0.04) and pathological metastasis (p = 0.01). Univariate analysis indicated that the patients with NDRG2 high expression correlated with favorable prognosis in patients with lung adenocarcinoma (p = 0.001), as opposed to CD24 (p = 0.001). The survival rate of the patients with NDRG2-low/CD24-high expression was the lowest (p < 0.001). Multivariate statistical analysis showed that the conjoined expressions of NDRG2-high/CD24-low and NDRG2-low/CD24-high were independent prognostic indicators of lung adenocarcinoma (p = 0.03 and p = 0.02, respectively). Our results suggest that the decreased expression of NDRG2 or the increased expression of CD24 is an important feature of lung adenocarcinoma. A combined detection of NDRG2/CD24 co-expression may benefit us in prediction of the prognosis of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.